This is a working overview of Whey protein, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Analytical testing for whey protein hydrolysate focuses on peptide size distribution, degree of hydrolysis, protein content, moisture, ash, and microbiological quality. Size-exclusion chromatography and mass spectrometry can characterize peptide profiles, while Kjeldahl or combustion methods estimate total nitrogen and protein. Amino acid analysis quantifies free and total amino acids. Because peptide mixtures are complex, no single method captures every property, and results can vary between laboratories. Standardized methods and reference materials help improve comparability, but full sequence-level characterization remains uncommon in routine quality control.
Regulatory treatment of whey protein hydrolysate depends on the country and intended use. In many jurisdictions it is regulated as a food ingredient or food for special dietary use, not as a drug. Labeling rules govern allergen statements, protein content claims, and ingredient names. Some markets have specific rules for infant formula ingredients, where hydrolysates may be used for particular dietary purposes. Regulations generally focus on safety, truthful labeling, and manufacturing standards rather than on therapeutic effects. Scientific questions about specific peptide activities remain an active area of research rather than a settled regulatory category.
Whey protein hydrolysate is derived from whey, the liquid byproduct of cheese-making or casein coagulation. It consists of peptides and free amino acids produced when peptide bonds are cleaved by enzymes or acid. Hydrolysis lowers the average molecular weight and can change solubility, viscosity, and bitterness. The degree of hydrolysis indicates the proportion of peptide bonds broken and distinguishes partial from extensive hydrolysates. Commercial ingredients vary widely in peptide size, mineral content, and lactose level.
Production usually starts with whey protein concentrate or isolate. The material is dissolved, pasteurized, and adjusted to conditions that favor a chosen protease, such as trypsin, pepsin, or papain. Enzyme choice, pH, temperature, and reaction time determine peptide length, terminal residues, and functional behavior. After hydrolysis, the enzyme is inactivated by heat or pH change, and the liquid is clarified, filtered, concentrated, and dried. Membrane filtration can further fractionate peptides and remove some minerals or lactose. The final powder is typically spray-dried.
Composition reflects the whey source and the extent of hydrolysis. Beta-lactoglobulin and alpha-lactalbumin fragments are common, and sweet whey may contribute glycomacropeptide. The amino acid profile remains broadly similar to intact whey protein, but peptide size affects how quickly nitrogen appears in blood after ingestion. Bitter notes often arise from short peptides with hydrophobic residues. Hydrolysates are used in sports nutrition, infant formula, and clinical nutrition, though effects on muscle, immunity, or allergy risk are separate research questions rather than guaranteed properties.
| Property | Value | Notes |
|---|---|---|
| Moisture content | Typically below 6% for dry powders | Higher moisture can promote caking and degradation. |
| Water activity | Often below 0.6 | Low water activity limits microbial growth. |
| Typical storage temperature | 15–25 °C (cool, dry) | Avoid heat and humidity; follow label specifications. |
| Common analytical method | Size-exclusion chromatography | Used to estimate peptide molecular weight distribution. |
| Common synonym | Hydrolyzed whey protein | Not identical to whey protein isolate or concentrate. |
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with enzymes or, less often, acid or heat to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese making, first concentrated and dried into whey protein concentrate or isolate. Hydrolysis shortens long protein chains into smaller peptides, changing functional properties such as solubility, viscosity, and foam formation. The resulting powder contains peptides, residual intact protein, moisture, minerals, and variable amounts of lactose and fat depending on the starting material.
Enzymatic hydrolysis usually uses proteases from microbial, plant, or animal sources. The enzyme choice, pH, temperature, and reaction time determine which peptide bonds are cleaved and the final peptide profile. After hydrolysis, the enzyme is inactivated by heat, and the mixture is clarified, filtered, concentrated, and spray-dried. Manufacturers may use ultrafiltration to remove larger peptides or minerals. The degree of hydrolysis, often reported as a percentage, describes the proportion of peptide bonds broken. A higher degree generally means shorter peptides, but it does not by itself define taste, allergenicity, or biological activity.
Whey protein hydrolysate appears in foods, infant formula, sports nutrition, and specialized clinical nutrition. Its production can reduce viscosity and improve heat stability compared with intact whey protein. Bitterness is common because short hydrophobic peptides can activate bitter taste receptors. The ingredient is not the same as free amino acids; it remains a mixture of peptides of different lengths. Composition varies by supplier, enzyme, and process, so two hydrolysates with the same protein content may behave differently in a formulation.
Enzyme choice, pH, temperature, time, and substrate concentration influence the resulting peptide distribution. Endopeptidases cut internal peptide bonds, while exopeptidases remove terminal amino acids and can reduce bitterness. Manufacturers may combine enzymes or use membrane filtration to select peptide size ranges. A higher degree of hydrolysis generally means more small peptides and free amino acids, but it does not by itself define biological activity or nutritional quality. Batch-to-batch variation arises from raw whey composition, enzyme specificity, and processing parameters, so specification ranges are common in commercial supply.
Dried hydrolysate powders are usually off-white to pale yellow and are marketed as free-flowing powders or liquid concentrates. They are used in foods, beverages, and specialized nutrition products where rapid dispersion or reduced allergenicity is desired, although residual allergenic epitopes can remain depending on hydrolysis extent. The term hydrolysate does not imply a single molecular weight cutoff or a guaranteed clinical effect. Labels may state degree of hydrolysis, protein content, or peptide length profile, but analytical definitions vary across suppliers and jurisdictions.
=== Glycemic Control === Glycemic control is a medical term referring to the typical levels of blood glucose in a person with diabetes mellitus. Much evidence suggests that many of the long-term complications of diabetes, result from many years of hyperglycemia (elevated levels of glucose in the blood). "Perfect glycemic control" would mean that glucose levels were always normal (70–130 mg/dL or 3.9–7.2 mmol/L) and indistinguishable from a person without diabetes. Good glycemic control, in the sense of a "target" for treatment, has become an important goal of diabetes care. Poor glycemic control refers to persistent (over several months) elevated blood glucose in the 200 to 500 mg/dL (11–28 mmol/L) range. This is also measured by Hb A1c levels, which may range 6.5% or higher.
== I == idiopathic – idiopathic thrombocytopenia purpura – IHS – immune complex – immune deficiency/immunodeficiency – immune response – immune system – immune thrombocytopenic purpura – immunity – immunization – immunocompetent – immunocompromised – immunodeficiency – immunogen – immunogenicity – immunoglobulin (Ig) – immunoglobulin A (IgA) – immunoglobulin D (IGD) – immunoglobulin E (IGE) – immunoglobulin G (IGG) – immunoglobulin M (IGM) – immunomodulator – immunostimulant – immunosuppression – immunotherapy – immunotoxin – in vitro – in vivo – incidence – Incubation period – IND – Indian Health Service (IHS) – infection – infectious – informed consent – infusion – inoculation – institutional review board (IRB) – integrase – integrase inhibitors – Interaction – interferon – interleukin-1 (IL-1) – interleukin-2 (IL-2) – interleukin-4 (IL-4) – interleukin-12 (IL-12) – interleukins – International Center for Research on Women – intramuscular (IM) – intravenous – intravenous immunoglobulin (IVIG) – intravitreal – Investigational New Drug (IND) – IRB – ITP – IVIG
The Litton detector was developed for sampling the light energy distribution in the rear focal-plane of a spherical lens for sampling geometric relationships and the spectral density distribution of objects recorded on film transparencies. The application of the Litton detector by Salzman et al. provided measurement at 32 small scattering angles between 0° and 30°, and averaging over a broad range of azimuthal angles as the most important angles are the forward angles for static light scattering. By 1980, Bartholi et al. had developed a new approach to measuring the scattering at discrete scattering angles by using an elliptical reflector to permit measurement at 30 polar angles over the range 2.5° ≤ θ ≤ 177.5° with a resolution of 2.1°. The commercialization of multiangle systems began in 1977 when Science Spectrum, Inc. patented a flow-through capillary system for a customized bioassay system developed for the USFDA. The first commercial MALS instrument incorporating 8 discrete detectors was delivered to S.C. Johnson and Son, by Wyatt Technology Company, in 1983, followed in 1984 with the sale of the first 15 detector flow instrument (Dawn-F) to AMOCO. By 1988, a three-dimensional configuration was introduced specifically to measure the scattering properties of single aerosol particles. At about the same time, the underwater device was built to measure the scattered light properties of single phytoplankton. Signals were collected by optical fibers and transmitted to individual photomultipliers.
Sources: en.wikipedia.org
Alcohol has a long association of military use, and has been called "liquid courage" for its role in preparing troops for battle, anesthetizing injured soldiers, and celebrating military victories. It has also served as a coping mechanism for combat stress reactions and a means of decompression from combat to everyday life.
=== Alternative routes of administration === In rhesus macaques, BCG shows "unprecedented" rates of TB protection when given intravenously. Some risks must be evaluated before it can be translated to humans. The University of Oxford Jenner Institute is conducting a study comparing the efficacy of injected versus inhaled BCG vaccine in already-vaccinated adults.
=== Shrinkage and swelling === Shrinkage and swelling may occur in wood when the moisture content is changed. Shrinkage occurs as moisture content decreases, while swelling takes place when it increases. Volume change is not equal in all directions. The greatest dimensional change occurs in a direction tangential to the growth rings. Shrinkage from the pith outwards, or radially, is usually considerably less than tangential shrinkage, while longitudinal (along the grain) shrinkage is so slight as to be usually neglected. The longitudinal shrinkage is 0.1% to 0.3%, in contrast to transverse shrinkages, which is 2% to 10%. Tangential shrinkage is often about twice as great as in the radial direction, although in some species it is as much as five times as great. The shrinkage is about 5% to 10% in the tangential direction and about 2% to 6% in the radial direction. Differential transverse shrinkage of wood is related to:
Sources: en.wikipedia.org
== Risk factors == Although it is difficult to predict which individuals will be affected from drug-induced long QT syndrome, there are general risk factors that can be associated with the use of certain medications. Generally, as the dose of a drug increases, the risk of QT prolongation increases as well. In addition, factors such as rapid infusion, concurrent use of more than one drug known to prolong QT interval, diuretic treatment, electrolyte derangements (hypokalemia, hypomagnesemia, or hypocalcemia), advanced age, bradyarrhythmias, and female sex have all been shown to be risk factors for developing drug-induced QT prolongation. TdP has been shown to occur up to three times more often in female patients compared with males, likely as a result of post-pubertal hormonal influence on cardiac ion channels. The QTc interval is longer in females, as well as having a stronger response to IKr-blocking agents. In males, the presence of testosterone upregulates IKr channels and therefore decreases QT interval. Stated otherwise, estrogens prolong the QT interval, while androgens shorten it and decrease the response to IKr-blocking agents. Structural heart disease, such as heart failure, myocardial infarction, and left ventricular hypertrophy, are also risk factors. Diuretic-induced hypokalemia and/or hypomagnesemia taken for heart failure can induce proarrthymia. The ischemia that results from myocardial infarctions also induce QT prolongation.
=== Ribosome-mediated attenuation === In this situation RNA polymerase is dependent on (lagging) ribosome activity; if the ribosome pauses due to insufficient charged tRNA then the anti-terminator structure is favoured. The canonical attenuator example of the trp operon uses this mechanism in E. coli. Similar regulatory mechanisms have been found in many amino acid biosynthetic operons.
Functional KORs are present on nerve terminals of both oxytocin and vasopressin neurons in the rat neurohypophysis, where agonists inhibit potassium-evoked hormone release. Both dynorphin1-8 and (1–17) suppress stimulated oxytocin release from isolated neurosecretory endings, with effects on the initial and secondary peaks of hormone secretion, while exerting no influence on vasopressin release under similar conditions. These interactions extend to plasma hormone levels, where KOR agonists decrease circulating oxytocin concentrations, while antagonists increase oxytocin release, suggesting that KOR signaling mediates negative regulation of oxytocin secretion during stress or physiological challenges.
== Chemistry == 1,2-Diarylethylamines contain the substructure ArCH2CH(Ar')NRR', where Ar, Ar' = aryl and R, R' = H or organyl. A chiral center exists at the ethylamine carbon atom bearing the two aryl groups. The enantiomers often have a large difference in pharmacological activity. For example, (+)-(S)-diphenidine has 40 times higher affinity than (−)-(R)-form for the NMDA receptor. According to a review by Jason Wallach and Simon Brandt (2018), most psychoactive 1,2-diarylethylamines reported in the scientific literature contain non-heteroaromatic aryl groups (i.e., both rings are carbocyclic). Some exceptions include lanicemine and an analogue N-ethyl-lanicemine, which feature a heteroaromatic pyridyl ring. Additional heteroaromatic analogues have been disclosed in the patent literature.
Sources: en.wikipedia.org
It is generally stored in a sealed container in a cool, dry place away from strong odors. Moisture and heat can cause caking, flavor changes, and peptide degradation. Product-specific labels and stability data should guide actual storage conditions.
Common tests measure moisture, water activity, protein content, ash, microbiological safety, and degree of hydrolysis. Peptide size distribution may be checked by chromatography. Not every batch receives full sequence-level analysis because such testing is complex and costly.
Not necessarily, because hydrolysis can reduce the size of some allergenic proteins while residual allergenic sequences may remain depending on the process. Milk is still a major allergen, and labeling rules usually require milk allergen disclosure unless a specific exemption applies. The term hydrolysate alone does not establish hypoallergenicity.
Whey protein hydrolysate is whey protein that has been treated with enzymes or acid to break peptide bonds into smaller peptides. It is not a different protein source; it is a modified form of whey protein. Commercial products range from partially to extensively hydrolyzed.